Hypertension Research
Online ISSN : 1348-4214
Print ISSN : 0916-9636
ISSN-L : 0916-9636
Clinical studies
Safety and Availability of Doxazosin in Treating Hypertensive Patients with Chronic Renal Failure
Yasukiyo MORIHiroaki MATSUBARAAtsuko NOSEYasunobu SHIBASAKIHiroya MASAKIAtsushi KOSAKIMitsuhiko OKIGAKISoichiro FUJIYAMAYoko TANAKA-UCHIYAMATakamasa HASEGAWAOsamu IBAEriko TATEISHIKatsuya AMANOToshiji IWASAKA
Author information
JOURNALS FREE ACCESS

2001 Volume 24 Issue 4 Pages 359-363

Details
Abstract

Hypertension accelerates the progression of renal disease in patients with chronic renal failure. Doxazosin, an α1-antagonist, is an antihypertensive agent with a long half-life. In this study, 15 patients with chronic renal failure were treated only with doxazosin and diuretics for 6 months and their blood pressure, renal parameters and lipid profile were measured. The initial dose of doxazosin was 2 mg/day and it was titrated until blood pressure was normalized. The average dose was 5.6 mg/day. As expected, systolic and diastolic blood pressure were decreased with treatment (165/91 mmHg to 135/73 mmHg). The drop in blood pressure was associated with an increase in glomerular filtration and a decrease in plasma BUN and creatinine levels. Reduction in mean blood pressure and decrease in proteinuria had a significant positive correlation (r=0.048, p=0.007). Proteinuria was decreased from 1.8 mg/day to 1.3 mg/day with doxazosin treatment and triglycerides also decreased, while HDL-cholesterol was increased. No side effects were observed. These results indicate that doxazosin is an efficient depressor agent with renal protective actions and that higher doses of doxazosin can be safely given to patients with chronic renal failure. (Hypertens Res 2001; 24: 359-363)

Information related to the author
© 2001 by the Japanese Society of Hypertension
Previous article Next article
feedback
Top